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properties. Of these, Agaricus subrufescens, also known as the ‘‘almond mushroom’’, has long been
valued by many societies (i.e., Brazil, China, France, and USA). Since its discovery in 1893, this
mushroom has been cultivated throughout the world, especially in Brazil where several strains of
A. subrufescens have been developed and used as health food and alternative medicine. This article
presents up-to-date information on this mushroom including its taxonomy and health promoting
beneﬁts. Medicinal properties of A. subrufescens are emphasized in several studies which are
reviewed here. In addition, safety issues concerning the use of this fungus will be discussed.
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Mushrooms are popular and valuable foods, which are low in
calories but maybe higher in minerals, protein and ﬁber
(Firenzuoli et al., 2008). Their beneﬁcial biochemical proper-
ties have also attracted much attention as functional health
foods (Gonzaga et al., 2005; Dai et al., 2009). All edible mush-
rooms are high in vitamin B plus other vitamins such as vita-
min C and ergosterol. Mushrooms have historically been used
as medicines and tonics (Horm and Ohga, 2008) with Lentinula
edodes (Berk.) Pegler (Shitake), Grifola frondosa (Dicks.) Gray
(Maitake), Ganoderma lucidum (Curtis) P. Karst (Reishi),
Cordyceps sinensis (Berk.) Sacc. and Hericium erinaceus (Bull.)
Persoon being used in traditional Chinese medicine formula-
tions (Dai et al., 2009). Bioactive compounds from edible
mushrooms have become new products for health therapy,
especially anti-cancer therapies (Ramberg et al., 2010). Studies
on anti-cancer properties of mushrooms have revealed the pos-
sibility of developing mushrooms as alternative medicines
(Ramberg et al., 2010). Wasser (2002) and Ramberg et al.
(2010) have reviewed the use of mushrooms as sources ofFigure 1 Agaricus subrufescens. (A) basidiocaanti-tumor and immunomodulatory compounds. In this paper
we focus on Agaricus subrufescens Peck and its medicinal
properties.
A. subrufescens was called the ‘‘almond mushroom’’ due to
its almond taste, and cultivated and consumed in the Atlantic
states of the United States from the late 19th to the early 20th
century (Kerrigan, 2005). In 1960, this mushroom was discov-
ered again in Brazil, and called the ‘‘Piedade mushroom’’ due
to the name of the village, in the Province of Sao Paolo, where
it was collected by T. Furumoto who sent it to Japan in 1965 to
study its medicinal properties. This mushroom was identiﬁed
as Agaricus blazei Murrill by the Belgian botanist P. Heine-
mann in 1967. Other common names for this mushroom are
Himematsutake in Japan, medicinal mushroom or Sun Mush-
room (Cogumelo do Sol in Portuguese) in Brazil, and Royal
Sun Agaricus in other countries. After the death of Furum-
oto, the cultivation of A. blazei was abandoned in Japan, but
because of the interest in the Japanese market, mushroom cul-
tivation commenced in Brazil. A. subrufescens had become an
important export product for Brazil, fetching higher prices in
comparison to other mushrooms (Souza Dias et al., 2004).rp, (B) Schaeffer’s cross-reaction on pileus.
Agaricus subrufescens: A review 133The aim of this present paper is to summarize the available
information on A. subrufescens, including its taxonomy, phy-
logeny, distribution, various health beneﬁts and current status
of scientiﬁc research.
2. Characteristics and taxonomy
A. subrufescens Peck is a gilled fungus belonging to the family
of the Agaricaceae in the order Agaricales (Firenzuoli et al.,
2008) within the phylum Basidiomycota. It is a saprobe and
inhabits rotting leaves often at the borders between forests
and parks (Fig. 1). This mushroom is discovered in North
America and later South America. However, it has also been
found outside America, in Europe, Hawaii, and Thailand
where it grows under forest trees and in parks and gardens
(Kerrigan, 2005; Arrillaga and Parra, 2006; Dai et al., 2009;
Wisitrassameewong et al., 2011).
A. subrufescens has been thoroughly described by Kerrigan
(2005) and the illustration and description was also published
by Firenzuoli et al. (2008) and by Wisitrassameewong et al.
(2011). The basidiomata morphology of this species is variable.
Sporocarps can be robust or gracile, both due to the genotype
and environmental inﬂuences (Kerrigan, 2005). The cap is 20–
70 mm broad in button stage and 60–150 mm broad in mature
stage hemispherical to convex to plano-convex shape and ﬂe-
shy. The surface is dry and covered by ﬁbrillose squamulose
hairs. The pileus color is somewhat variable and sensible to
the light, ranging from brownish-gold, reddish brown, purple
brown to brownish orange, more or less pale and sometimes
completely white. The basidiospores are chocolate brown
(5 · 4 lm) (Firenzuoli et al., 2008; Wisitrassameewong et al.,
2011). The specimens from Thailand differ from those previ-
ously reported in terms of size, sturdiness and length of stipe,
which were larger, more virgate and fragile than those found in
America; their cap color is more reddish than those of the
European taxa. The stipe is also highly variable which could
be short and ﬁrm or more slender and virgate (Kerrigan,
2005). However, the cap shape and lamellae color were in con-
cordance with those reported by Firenzuoli et al. (2008) from
Brazil. The small cottony ﬂoccules beneath the remnant partial
viel are a consistent character of the species (Peck, 1893;
Kerrigan, 2005). This important feature is also found in Thai
taxa. The morphological variability of this species may be
inﬂuenced by different climates and ecosystem.
From a nomenclatural point of view, taxonomists agree
that the species has been incorrectly referred as A. blazei
Murrill. Therefore it was proposed by Wasser et al. (2002) as
a new species, Agaricus brasiliensis Wasser, Didukh, de
Amazonas & Stamets, and then synonymised by Kerrigan
(2005) with A. subrufescens which has priority since it is older.
Callac (2007) noted that A. brasiliensis was illegitimate because
it is a later homonym of A. brasiliensis Fr. 1830. For taxonomy
and synonymy of this taxon we have followed Kerrigan (2005),
Arrillaga and Parra (2006) and Ludwig (2007). A. subrufescens
Peck was published in 14 March 1894 and has priority over
Agaricus subrufescens Ellis & Everh. which was published in
29 March 1894 as ‘Agaricus (Tricholoma) subrufescens’ accord-
ing to a recent updating in Index Fungorum (see http://
www.indexfungorum.org/names/Names.asp) and MycoBank
(http://www.mycobank.org/MycoTaxo.aspx).
Agaricus subrufescens Peck, Ann. Rep. N.Y. St. Mus. 46: 25
(1893).= Agaricus subrufescens Ellis & Everh., Proc. Acad. nat. Sci.
Philad. 45: 440 (1894) is a homonym of the earlier name.
= Psalliota subrufescens (Peck) Kauffman, 1918, Publications
Mich. geol. biol. Surv., Biol. Ser. 5 26, 239.
= Agaricus rufotegulis Nauta, 1999 Persoonia 17, 230.
Misapplied names:
Agaricus blazei Murrill, 1945, 8, 193.
Agaricus blazei Murrill sensu Heinemann, 1993 Bull Jard
Bot Belgium 62, 653.
Illegitimate name:
Agaricus brasiliensisWasser, M. Didukh, Amazonas & Sta-
mets, in Wasser, Didukh, Amazonas, Nevo, Stamets & Eira,
International Journal of Medicinal Mushrooms (Redding)
4(4): 274 (2002) Nom. illegit., Art. 53.1, a homonym of
Agaricus brasiliensis Fr. 1830.
Wasser et al. (2002) rejected conspeciﬁcity between
specimens from Brazil belonging to A. blazei Murrill sensu
Heinemann and those from north America belonging to A.
subrufescens Peck, based on size and shape of fruiting bodies
and pileal surface, type of pileal covering, presence of cheilocy-
stidia and spore size. Kerrigan (2005) however, showed that a
cultivated specimen originating from Brazil and a wild speci-
men from USA (California) belonged to the same species
based on biological and phylogenetic approaches. Firstly, the
two specimens were interfertile and ﬁrst generation fertile hy-
brids were produced. Secondly, the north and south American
specimens had 100% similarity of ITS1+2 sequences, which
were produced from the ITS1 and ITS4 primers (White
et al., 1990). Kerrigan (2005) also extended the synonymy to
A. rufotegulis Nauta described for European specimens which
also exhibited similar ITS1+2 sequences, however, interfertil-
ity between European and American specimens has not been
tested. Finally, some specimens from Hawaii were also in-
cluded in A. subrufescens but their ITS1+2 sequences slightly
diverged from those of others (Kerrigan, 2005). Until other se-
quence data become available and interfertility tests are per-
formed, we exclude neither the existence of infraspeciﬁc taxa,
nor the fact that A. subrufescens might be a complex of species.
This caution however, concerns only the non American
populations, because the synonymy between A. blazei Murrill
sensu Heinemann from south America and A. subrufescens
Peck from north America appears to be indisputable. The ma-
jor argument that Wasser et al. (2002) used against synonymiz-
ing A. blazei with A. subrufescens was the divergence that
appeared in the phylogenetic trees of Geml et al. (2004) in
which ‘A. blazei’ and ‘A. subrufescens’ highly diverge, in con-
tradiction with the results of Kerrigan (2005). However, not
only was the identiﬁcation of the strain W17 used to represent
A. subrufescens not conﬁrmed because sporophores of W17
were not examined or reported, but also a simple examination
of the sequence of W17 used in the study of Geml et al. (2004,
GenBank accession number AY484674), showed that its ITS1
region is close to ITS1 sequences of species belonging to the
section Arvenses, which its ITS2 region is similar (a single dif-
ferent character) to many ITS2 sequences of Agaricus bisporus
(the button mushroom, see for example GenBank accession
number DQ404388, isolate AFTOL-ID 448). A. bisporus be-
longs to the non related section Bivelares and differs from
any other ITS2 sequence of A. subrufescens or A. blazei at
Table 1 Bioactive compounds from Agaricus subrufescens.
a-(1–4)-; b-(1–6)-glucan Fujimiya et al., 1998
a-(1–6)-; a-(1–4)-glucan Mizuno et al., 1990
b-(1–6)-; b-(1–3)-glucan Mizuno et al., 1990
b-(1–6)-; a-(1–3)-glucan Mizuno et al., 1990
Lectin Kawagishi et al., 1990
Riboglucan Cho et al., 1999
Glucomannan Hikichi et al., 1999
b-(1–2)-; b-(1–3)-
glucomannan
Tsuchida et al., 2001,
Mizuno et al., 1999
Ergosterol Takaku et al., 2001
Sodium pyroglutamate Kimura et al., 2004
RNA–protein complex Gao et al., 2007
Agaritine Stijve et al., 2003
Blazein Itoh et al., 2008
134 K. Wisitrassameewong et al.about 30 positions. The deposited sequence of W17 probably
results from an accidental assemblage of sequences from two
different strains.
In conclusion, A. subrufescens Peck is a species distributed
in north and south America. We provisionally include in this
species other populations known in Europe, Oceania and Asia.
Further studies will be necessary to determine the biological
and genetic divergence between these populations. Large phe-
notypic variability is generally found inside and between
populations of some other species of Agaricus having a large
distribution range across several continents. For example, in
A. bisporus, three varieties were described based on biological,
genetic and morphological traits; these varieties remain inter-
fertile, but have different life cycles (Kamzolkina et al.,
2006); however tropical populations of this species, reported
by Heinemann (1956) have never been studied. In contrast,
Agaricus subﬂoccosus (Lange) Pilat has been ﬁrst considered
as a species complex (Kerrigan et al., 1999); but the two main
homothallic lineages being intersterile and having different
habitats were ﬁnally elevated at the species rank (Kerrigan
et al., 2008). These two examples show how the life cycle
can have an impact on the population structure, on the
speciation processes, on the circumscription of the species,
and ﬁnally on the taxonomy. In comparison, A. subrufescens
is poorly known: population genetic and life cycle studies of
A. subrufescens are almost lacking. For example, a biological
approach of Kerrigan (2005) suggested that A. subrufescens
have an amphithallic life cycle (partly heterothallic and partly
pseudohomothallic), while a recent cytological approach
(Souza dias et al., 2008) suggested that the life cycle be hetero-
thallic. In such conditions, taking into account that reproduc-
tive biology and genetic resources are crucial knowledge for
strain improvement in species of interest, and more taxonomic
inference seems therefore premature. Instead, one can appreci-
ate the large available variability existing in this species (or
species complex), now extended to Thailand, and its potential
for human health.
In this review we refer to the mushroom as A. subrufescens
and treat results of studies on mushrooms named as A. blazei
and A. brasiliensis as this species. However, all the data con-
cerning the medicinal properties reported are based on studies
of a limited number of isolates, all or nearly all of them from
the local population in Brazil. It is likely that medicinal prop-
erties may differ qualitatively or quantitatively among otherpopulations. It appears that the genetic resources of this spe-
cies remain signiﬁcantly underutilized.3. Chemical composition
The fruiting bodies of A. subrufescens contain 89–91% water,
which is in general less than that of A. bisporus. Almost 48% of
total dry matter consists of crude protein and 18% of carbohy-
drates, but the lipid content is only 0.5% (Gyo¨rﬁ et al., 2010).
The fruiting bodies of A. subrufescens contain high levels of
valuable minerals, e.g. potassium, phosphorus, calcium, mag-
nesium and zinc. Nevertheless, a minute amount of cadmium
was also detectable (Gyo¨rﬁ et al., 2010).
Bioactive compounds of mushrooms can be isolated from
their fruiting bodies, or culture extraction from pure culture
of mycelia (Chang and Miles, 2004). A. subrufescens has been
reported to produce various bioactive compounds that have
potential to treat many diseases (Firenzuoli et al., 2008). This
mushroom has been used as a medicinal food for the preven-
tion of cancer, diabetes, hyperlipidemia, arteriosclerosis, and
chronic hepatitis, and is known to stimulate the immune sys-
tem (Takaku et al., 2001).
Several categories of molecules are involved in beneﬁcial ef-
fects of A. subrufescens and most of them are common to the
entire fungal kingdom (Levitz, 2010). Some compounds (such
as ergosterol and b-glucans) are considered as biochemical
markers for the kingdom and are ubiquitous. b-Glucans are
cell wall constituents that can be found in many fungi (Levitz,
2010). A list of bioactive compounds identiﬁed in A. subrufes-
cens is given in Table 2.
The bioactive compounds isolated from A. subrufescens are
mainly polysaccharides such as riboglucans (Cho et al., 1999),
b-glucans (Gonzaga et al., 2005; Fujimiya et al., 1998; Mizuno
et al., 1990) and glucomannans (Hikichi et al., 1999). Chemical
analysis of polysaccharides in A. subrufescens has been mea-
sured using High Performance Liquid Chromatography
(HPLC) (Volman et al., 2010). A. subrufescens polysaccharide
consists of 57.7% glucose, 27.7% galactose, 7.3% mannose/
xylose, and 4% fucose (Volman et al., 2010). Structural analy-
sis of b-glucans with 1–4 and 1–6 linkages showed they were
presented in a ratio of about 1:1. A small proportion of 1–3
linkages was also detected (Volman et al., 2010). More re-
cently, a new conﬁguration of polysaccharide puriﬁed from
A. subrufescens has been proposed (Liu et al., 2011). The puri-
ﬁed polysaccharide had a (1–6)-linked a-D-glucopyranosyl
backbone and one terminal (1-)-a-D-glucopyranosyl branch
along the main chain in a ratio of 1:1:1 (Liu et al., 2011; Liu
and Sun, 2011). The extract probably existed in a triple-strand
helical conformation in water (Liu et al., 2011). Alkaline
extraction and methylation analysis of puriﬁed polysaccharide
from A. subrufescens showed six types of residues (Liu and
Sun, 2011). The extract had a backbone consisting of (1–6)
linked-b-D galactopyranosyl, (1–6) linked-b-D glucopyranosyl
and (1–3,6)-linked b-D glucopyranosyl residues and branched
with three terminal (1-)-b-L-fucopyranosyl, (1-)-b-L-arabinof-
uranose and (1-)-b-D glucopyranosyl unit at the O-3position
of (1–3,6)-linked-a-D-glucopyranosyl along the main chain in
the ratio of 20:10:10:6:2:2 (Liu and Sun, 2011).
Anti-tumor activity has been found in lipid fractions of A.
subrufescens (Takaku et al., 2001). The bioactive substance
with the anti-tumor effect was puriﬁed and then identiﬁed as
Table 2 Beneﬁcial properties from Agaricus subrufescens that
have been published.
Medicinal properties References
Tumor growth
reduction
Mizuno et al., 1990;
Takaku et al., 2001; Itoh
et al., 2008; Kim et al.,
2009; Gonzaga et al.,
2009; Niu et al., 2009; Yu
et al., 2009; Ohno et al.,
2001; Itoh et al., 1994; Ito
et al., 1997; Kawagishi
et al., 1989, 1990; Kimura
et al., 2004,
Pinto et al., 2009, Jumes
et al., 2010
Immunomodulatory
activities
Liu et al., 2008, Chan
et al., 2007; Kimura et al.,
2004; Niu et al., 2009;
Ramberg et al., 2010
Immunostimulatory
eﬀects
Kasai et al., 2004;
Kaneno et al., 2004;
Yuminamochi et al., 2007;
Førland et al., 2010, 2011;
Johnson et al., 2009;
Kozarski et al., 2009;
Sorimachi et al., 2001;
Endo et al., 2010;
Fujimiya et al., 1998
Antimicrobial
activities
Bernardshaw et al., 2005;
Bernardshaw et al.,2006
Antiviral activities Bruggemann et al., 2006;
Faccin et al., 2007
Anti-allergy eﬀects Ellertsen and Hetland
2009
Agaricus subrufescens: A review 135ergosterol (Takaku et al., 2001). Ergosterol is functionally an
analog of mammalian cholesterol. It is a component of the
fungal cell membrane and has been described as the beneﬁcial
component in some medicinal mushrooms such as Lentinus
edodes (Berk) Pegler (Jasinghe and Perera, 2005), A. bisporus
(J.E. Lange) Imbach (Lindequist et al., 2005; Volman et al.,
2010), Grifola frondosa (Dicks.) Gray (Lindequist et al.,
2005) and Ganoderma lucidum (Curtis) P. Karst (Lindequist
et al., 2005).
Other bioactive molecules providing medicinal beneﬁts in
A. subrufescens are sodium pyroglutamate which has anti-
angiogenic and has anti-tumor and anti-metastatic properties,
as well as immune-modulator activity (Kimura et al., 2004).
An RNA–protein complex enriched fraction is cytotoxic by
stimulating the apoptosis pathways and has in vitro anti-tumor
activity (Gao et al., 2007). A. subrufescens lectin, a glycopro-
tein normally associated with b (1-6)-glucan, is characterized
by Kawagishi et al. (1990) and claims to have anti-tumor activ-
ity. Aromatic hydrazines, especially agaritine and its deriva-
tives also occur in A. subrufescens (Nagaoka et al., 2006).
The agaritine extracted from A. subrufescens exerts an
in vitro anti-tumor activity in leukemic cells with no signiﬁcant
effects on normal lymphatic cells. The cytotoxicological effect
of agaritine has been demonstrated on leukemic cell lines with
an IC50 of 2.7–16 lg/ml. (Endo et al., 2010; Akiyama et al.,
2011). The agaritine concentration is comparable to the con-
centration obtained from A. bisporus, and is approximately1.8 mg/g dry weight (Stijve et al., 2003; Nagaoka et al.,
2006). Blazein (named after the synonym A. blazei) is a steroid
derivative found in A. subrufescens with an in vitro anti-cancer
activity on human lung cancer LU99 cells without affecting
normal human lymphocytes (Itoh et al., 2008).
4. Pharmaceutical properties
A. subrufescens is a well-known medicinal mushroom used in
many countries, and thus consumption of this mushroom
is used as an alternative way to cure diseases. Various
pharmaceutical activities have been found associated with A.
subrufescens and researches to reveal the function of bioactive
compounds are extensive. Recent studies have been performed
in vitro and in vivo to conﬁrm the mushrooms therapeutic
properties (Firenzuoli et al., 2008). Identiﬁcation of (novel)
immunomodulating bioactive compounds from the mushroom
may also help in new treatments for patients suffering from
cancer and immunodeﬁciency (Ohno et al., 2001).
5. Anti-cancer and tumor suppressive activity
There have been many studies showing the anti-tumor activity
of A. subrufescens (Firenzuoli et al., 2008). In the last decade,
many bioactive substances (Table 1) have been shown to exhi-
bit the potential anti-tumor properties. The major anti-tumor
substances from A. subrufescens are polysaccharide-enriched
extracts and protein–bound polysaccharide complexes
(Kawagishi et al., 1989; Itoh et al., 1994; Ito et al., 1997).
Mushroom polysaccharides are thought to prevent oncogene-
sis, have shown an indirect anti-tumor activity against various
allogeneic and syngeneic tumors, and prevent tumor metastasis
(Kimura et al., 2004). The major polysaccharide fraction of A.
subrufescens extract is revealed as b-glucan (Ohno et al., 2001).
The anti-tumor mechanisms of A. subrufescens extracts have
been shown by oral administration in different laboratory mice
models such as Sarcoma 180-implanted bearing mice (Takaku
et al., 2001), Meth-A ﬁbrosarcoma tumor-bearing mice
(Kawagishi et al., 1989, 1990; Mizuno et al., 1990, 1998; Itoh
et al., 1994; Fujimiya et al., 1998; Takaku et al., 2001) and
BALB/c nu/nu mice implanted leukemic model (Kim et al.,
2009). Gonzaga et al. (2005) extracted the polysaccharide-
complex from A. subrufescens and characterized a glucan–
protein complex by FTIR, 13C NMR and 1H NMR spectros-
copy. The extract exhibits both of a and b glycosidic linkage of
glucans. The result indicates that b-glucans are the predomi-
nant structures as compared to a-glucans.
A. subrufescens extracts may be cytotoxic to tumor cells
in vitro and inhibit the growth of human leukemia cells by
inducing apoptosis (Jin et al., 2007), which directly inhibit
the in vitro growth of tumor cells (Jin et al., 2007; Kim
et al., 2009). Kim et al. (2009) used the agarose DNA fragmen-
tation assay (DNA laddering assay) and cell death detection
ELISA to demonstrate the induction of apoptosis in cancer
cell culture. Ethanol/water extracts or n-hexane extracts in-
duced in vitro apoptosis. Water and ethanol extracts have
slight or lacked direct inhibitory effects. The anti-tumor effect
on the implanted leukemia mice model may therefore have
been due to the enhancement of the host immune system.
Based on in vivo and in vitro results, they conclude that A.
subrufescens polysaccharides may not possess direct anti-leuke-
mic activity (Kim et al., 2009). Jin et al. (2007) also conﬁrmed
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to peptides 74:26) of A. subrufescens induced apoptosis in hu-
man leukemic U937 cells through down regulation of Bcl-2
and activation of caspase-3 and cleavage of poly (ADP-ribose)
polymerase-PARP. By using transfected U937 cells with Bcl-2
containing plasmids (i.e. increasing the Bcl-2 expression level)
the major regulators of the A. subrufescens extract inducing
apoptosis were shown to be Bcl-2 and caspace-3 associated
to the dephospholyration of the Akt cascade signal pathway.
A human prostate carcinoma cell line was used as a model
to investigate the anti-tumor inhibitory activity of polysaccha-
ride-enriched crude extracts (Yu et al., 2009). The activities of
caspase-3 and the DNA fragmentation were most enhanced in
treated prostate cancer cell lines. The crude extract containing
(1–3)-b-D-glucan probably inhibited the growth of prostate
cancer cells via an apoptotic pathway and expressed anti-pro-
liferation and anti-angiogenic mechanisms against prostate tu-
mor growth (Yu et al., 2009). A. subrufescens extracts may
affect angiogenesis mechanisms of tumor cells. Angiogenesis
obtains nutrients for growth and development of tumor cells
and thus this may inhibit their growth. Tumor inhibitory rate
in s180 xenograft models also increased in a dose-dependent
manner using low molecular weight polysaccharides (LMPAB)
isolated from A. subrufescens (Niu et al., 2009). The anti-angi-
ogenesis effect of LMPAB was found in chicken embryo cho-
rioallantonic membrane (CAM) angiogenesis.6. Anti-cancer and tumor suppressive activity of polysaccharides
It is well-known that crude extracts of A. subrufescens have
beneﬁcial medicinal properties, however, they are rather com-
plex and the mode of action of the components of the extracts
need to be established. Several studies have characterized the
constituents of A. subrufescens crude extracts (Gonzaga
et al., 2005) and polysaccharides have consistently been shown
to be the major ingredients (Gonzaga et al., 2005; Dong et al.,
2002; Ohno et al., 2001). Extensive research has been carried
out to elucidate the structures of polysaccharides and their
relationship with anti-tumor activity (Gonzaga et al., 2009).
Most anti-tumor compounds in fungi are generally attributed
to polysaccharides with b-(1–3) glucan branches. The main
polysaccharides in A. subrufescens are from the b-(1–6) glucan
protein complex (Ohno et al., 2001). b-Glucan is a well-known
component of the polysaccharide crude that is important in tu-
mor cell inhibition.
b-Glucan is a D-glucose molecule linked by glycosidic bond
at the b position. b-Glucans are well known as anti-tumor
agents that are naturally found in bacteria and fungi
(Firenzuoli et al., 2008). Several studies have isolated this bio-
active compound from fruiting bodies, mycelium and liquid
culture medium of mushrooms (Chang and Miles, 2004;
Boonyanuphap and Hansawasdi, 2011). A. subrufescens has
high content of b-(1–6)-(1–3) glucan (Kozarski et al., 2009)
and glucan–protein complex (Gonzaga et al., 2005). b-Glucans
are thought to enhance the immune system to suppress or kill
pathogens and cancer cells (Ohno et al., 2001), which appear to
indirectly inhibit tumor cells via activating different immune
responses. The anti-tumor effects of polysaccharides work by
speciﬁc and non-speciﬁc immune response activation. Tumor
size of Walker-256 tumor bearing rats was reduced after treat-
ing with four treatments of A. subrufescens (pure powderedbasidiocarp, aqueous, acid and alkaline extracts) (Jumes
et al., 2010). b-Glucan–protein complex polysaccharide also
shows strong in vivo antitumor effect against Sarcoma 180 cell.
Moreover, it also can increase the antitumor activity of other
chemotherapeutics (Gonzaga et al., 2009).
The b-glucan content has been measured in different stages
of A. subrufescens fruiting body development (Camelini et al.,
2005). Immature fruiting bodies, mature fruiting bodies with
immature spores and mature spores were used to elucidate
the amount and structural characterization of b-glucan. The
yield of b-glucan in mature fruiting bodies with immature
spores of A. subrufescens was slightly higher as compared to
immature fruiting bodies and mature fruiting bodies with ma-
ture spores. The important anti-tumor activity was linked to a
water-soluble b-(1–6)-(1–3)-glucan (Mizuno et al., 1990;
Camelini et al., 2005). However, no signiﬁcant difference in tu-
mor growth inhibition or in function of the different matura-
tion phases of A. subrufescens fruiting bodies was detected
(Moura˜o et al., 2009).7. Other promising agents
Other bioactive compounds, excluding polysaccharide and
protein polysaccharide complex extracts, have also been shown
to exhibit anti-tumor effects against tumor cells. Takaku et al.
(2001) used a puriﬁed lipid fraction of A. subrufescens to inves-
tigate the anti-tumor activity on sarcoma bearing mice. After
puriﬁcation, the bioactive compound was identiﬁed as ergos-
terol by 1H NMR and mass spectrometry (Takaku et al.,
2001). The neovascularization induced by Lewis lung carci-
noma cell packed chambers was inhibited by the intraperito-
neal administration of ergosterol at doses of 5, 10 and
20 mg/kg for 5 consecutive days (Takaku et al., 2001). Neovas-
cularization is critical for the growth of tumor cells and is med-
iated by physiological substances produced by the tumors.
Therefore, the inhibition of neovascularization is one of the
several potential ways for cancer therapy (Takaku et al., 2001).
Blazein has also been isolated from A. subrufescens, which
can induce DNA fragmentations in in vitro culture cell of hu-
man lung cancer LU99 and stomach KATOIII cancer cells
(Itoh et al., 2008). The formation of a DNA ladder on agarose
gel after cultivation in the presence of blazein indicated the
occurrence of apoptosis. In contrast, no induction of apoptosis
was observed by blazein in normal lymphocytes prepared from
healthy volunteers (Itoh et al., 2008). Itoh et al. (2008) sug-
gested that the activity of these compounds is speciﬁc for can-
cer cells and would not be destructive to healthy tissues.
However, there is little amount of literature concerning this
steroid compound. These ﬁndings suggest that the bioactive
compounds from A. subrufescens extract can inhibit the
growth of many types of cancer cells.
More recently, a new promising agent was recognized from
A. subrufescens as a candidate for cancer therapy (Barbisan
et al., 2002;Akiyama et al., 2011). Puriﬁed agaritine from A.
subrufescens exerted the anti-tumor activity against in vitro leu-
kemic tumor cells (Endo et al, 2010; Akiyama et al., 2011).
However, the action of agaritine differs from b-glucan which
indirectly suppresses proliferation of tumor cells. Agaritine
has been shown to be weakly cytotoxic to normal lymphatic
cells. In addition, mutagenicity test using Umu salmonella
was negative in contradiction with a previous mutagenicity
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by caspase activation via cytochrome c release from mitochon-
dria (Akiyama et al., 2011). However, the direct target of agar-
itine for apoptosis induction is still difﬁcult to understand.
8. Anti-genotoxicity activities
Some in vitro and in vivo genotoxic studies (e.g. DNA damage
and aberration tests) have been performed on chemical carci-
nogenesis models (Angeli et al., 2006, 2009; Barbisan et al.,
2002; Delmanto et al., 2001). It appears that A. subrufescens
extracts or polysaccharides enriched fractions have direct pre-
ventive effect against DNA damaged induced by known geno-
toxic chemicals (Menoli et al., 2001; Delmanto et al., 2001).
Cyclophosphamide is a clastogenic agent which induces dis-
ruption or breakages of chromosomes (Matsumoto and Clus,
2000). It has been used to study in preventive of chromosome
aberration test in animal models treated by A. subrufescens ex-
tracts. An aqueous solution from this mushroom inhibited
induction of micronuclei by cylophosphamide in bone marrow
and peripheral blood of treated Swiss mice (Delmanto et al.,
2001). An aqueous solution obtained from A. subrufescens
tea product and dried A. subrufescens reduced the frequencies
of mutagen methyl methanesulfonate (MMS) micronuclei
induction in Chinese hamster V79 cell lines (Menoli et al.,
2001). The comet assay and GST-P-positive liver foci develop-
ment were used to evaluate the inﬂuence of mushroom aque-
ous extracts on liver cell DNA damage and the initiation of
liver carcinogenesis. A. subrufescens extracts protected rat liver
cells against diethylnitrosamine induction. Diethylnitrosamine
is a genotoxic carcinogen that leads to the initiation of pre-
neoplastic hepatocytes (GST-P positive foci) (Barbisan et al.,
2002). Treatment with high concentrations of A. subrufescens
extract (11.5 mg/ml) signiﬁcantly reduced DNA damage, indi-
cating a protective effect against different doses of diethylni-
trosamine (DEN)-induced liver genotoxicity. Barbisan et al.
(2003) observed no protective effect of GST-P-positive liver
foci and the extract signiﬁcantly increased the number of posi-
tive foci. More recently, the genotoxic and preventive geno-
toxic effect of b-glucan enriched extract against chemicals
was evaluated in vitro in human lymphocyte cells and in
human hepatoma cell-Hep G2 cell lines (Angeli et al., 2006;
Angeli et al., 2009a, 2009b; Ishii et al., 2011). b-Glucan from
A. subrufescens extracts reduced DNA damage induced by
Benzo-a-pyrene (BaP) and H2O2 in the comet test, micronuclei
test and in a binding assay (BaP only).
9. Biological responses on the Immune System
Beneﬁcial properties of fungi on the human immune system
have been demonstrated for several decades (Lucas, 1957;
Chihara, 1969; Chihara et al., 1970; Ooi and Liu, 2000; Was-
ser, 2002). Many studies stated that the immune system can
be stimulated by fungal extracts and their polysaccharides or
protein–polysaccharides complexes (Lucas, 1957; Sternberg
et al., 1963; Wooles and Di Luzio, 1963; Chihara, 1969).
To protect against infections, the human body uses both in-
nate immunity, including physical barriers, phagocytes and
soluble mediators (e.g. complements), and adaptive immunity,
including antibodies and cytotoxic T cells, to destroy patho-
genic invaders and also prevent re-infections (Chan et al.,2007). It is consensual that cell mediated immunity (CMI) is
the main mechanism of defense concerning fungi (Blanco
and Garcia, 2008). In cell mediated immunity, the involvement
of predominant cell types, such as macrophages and other cell
types appears to depend on pathogen associated molecular
patterns from fungal genera (Romani, 2011). It also appears
that the elimination of fungi by an immune response occurs
via the innate immune cells such as antigen presenting cells,
monocytes and dendritic cells (Romani, 2011). In fact,
bioactive compounds from fungi are derived from cell wall
or structural compounds, such as b-glucan, chitin, mannan,
gluco-protein and lipids such ergosterol (Romani, 2011).
Therefore, many different fungal genera can share a common
antigen which is recognized by pattern recognition receptors
of host cells. However the fungal composition can also vary
with the morphotype which can differ with the morphologic
state, i.e. spores versus ﬁlamentous fungi, and yeast versus
pseudo-hyphae or hyphae in dimorphic fungi (Romani, 2004,
2008; Blanco and Garcia, 2008). Nevertheless, there have been
some studies reported that humoral immunity can protect
against fungal infection. Antibody production of the humoral
immunity has importance for protection against fungi (Blanco
and Garcia, 2008). The main actions of antibodies in fungal
infection involve prevention of adherence, antibody opsoniza-
tion, toxin neutralization and antibody-dependent cellular
cytotoxicity (Blanco and Garcia, 2008).
The critical point of the ﬁrst line defense of innate and ac-
quired immunity against fungi is the production of chemokines
in order to recruit lymphocytces (phagocytes, T and B cells) at
the fungal infection sites (Blanco and Garcia, 2008).
Chemokine production is generally activated by an invariant
recognition process involving invariant pathogen associated
molecular patterns. Pathogen associated molecular patterns
can be recognized by a series of pattern recognition receptors
of host cells in order to consequentially promote the activation
of the immune system e.g. chemokine, cytokine, phagocytosis
and defensin (Romani, 2011). The receptors involving pattern
recognition receptors consist of Toll-like receptors, C-type lec-
tin receptors, complement receptor 3 and Dectins receptors
(Brown, 2006; Romani, 2011). The immunostimulatory A.
subrufescens extracts also appear to interact with several pat-
tern recognition receptors and occur partly via innate immune
cells of cell-mediated immunity (CMI), involving proteo-glu-
can or glucans or even peptido-glucan and/or mannan residues
(Johnson et al., 2009, Førland et al., 2010). Therefore it ap-
pears that the stimulatory effect appears to be mainly mediated
by pattern recognition receptors including via the lectin-bind-
ing site for b-glucans in complement receptor 3 (Czop et al.,
1989; Vetvicka et al., 1996; Akramiene et al., 2007; Romani
2011). The b-glucans from A. subrufescens extracts may medi-
ate complement receptor 3 through the lectin-binding site
(Johnson et al., 2009; Førland et al., 2010) and subsequently
stimulated complement 3 which is a crucial component in the
complement system. Shimizu et al. (2002) also proposed the
activation of the alternative pathway in the complement sys-
tem by A. subrufescens particles.
The immunostimulatory and its responses of water and eth-
anol extract from A. subrufescens have been established in
many studies for the last decade. Immunotherapy has increas-
ingly been considered as an alternative way to treat cancers.
There are many clinical trials being carried out using fungi
and clinical results are showing potential (Ohno et al., 2001;
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subrufescens is rich in biological response modulators, such as
proteoglucans (Hetland et al., 2008). Anti-tumor, anti-
bacterial and anti-viral activities have been demonstrated by
the extracts from A. subrufescens (Ohno et al., 2001; Gonzaga
et al., 2009; Bernardshaw et al., 2005; Bernardshaw et al., 2006;
Bruggemann et al., 2006; Faccin et al., 2007; Firenzuoli et al.,
2008; Hetland et al., 2008). Those biological responses are per-
formed by stimulating or modulating the immunity (Hetland
et al., 2008).
Extracts of A. subrufescens have been used successfully as
adjuvant in DNA vaccine to improve their efﬁcacy against
hepatitis B virus (HBV) infection and foot-and-mouth disease
(FMDV) (Hetland et al., 2008). Grinde et al. (2006) have used
microarray examination to prove the activation of expression
level of some modulators in the immune system. The result
from hepatitis C virus patients administrated with A. subrufes-
cens extract, resulted in the increase of expression of the
IFN-a, b receptors. The up-regulation of this gene is involved
in cell signaling and cycling, as well as in transcriptional
regulation (Grinde et al., 2006).10. Cytokine induction
A. subrufescens is shown to stimulate cytokine production,
such as interleukin-12 (Kasai et al., 2004), interferon-c
(Yuminamochi et al., 2007) and natural killer (NK) activity
(Kaneno et al. 2004). NK cells are white blood lymphocytes
of the innate immune system that is recognized as important
for immune surveillance for tumor cells (Talmadge et al.,
1980; Smyth et al., 2002) and pathogen (Biron and Brossay,
2001; Yokoyama and Scalzo, 2002). According to the study
of Kasai et al. (2004), IL-12 is a cytokine known to be a critical
regulator of cellular immune responses. Cytokine is involved in
the activation of NK cells against tumor cells. It is induced
after administrated with hemicellulase derived mycelia extract.
Oral administration of the fraction also enhances the activity
of NK cells in the spleen. These results are consistent with
Yuminamochi et al. (2007), powdered dried fruiting bodies
and hemicellulase-digested component of A. subrufescens aug-
mented NK cells activation through IL-12 mediated IFN-c
production. IL12 exert a potent antitumor activity in different
murine tumors models. The IL-12 in vivo antitumor activity is
found to be mediated by NK and/or NKT (Smyth et al., 2002).
IL-12 sustains many biological activities including differentia-
tion of lymphocytes, activating the phagocytes, induction of
nitrogen oxide, induction of Th1 responses and NK cells
activation (Romani, 2011). The T-cells IL12/IFN-c driven re-
sponse is generally considered as central axis for protection
against fungi. (Romani, 2008).
The analysis of spleen lymphocytes of mice model after in-
take with b-glucans enriched fraction (a-1,4 and/ or b-1,6
branched glucans) of A. subrufescens demonstrated the stimu-
lation of spleen lymphocyte such as cytotoxic T-cells even in
normal mice (Mizuno et al., 1998). Hemicellulases-treated
mycelia extract of A. subrufescens was also suggested to be in-
volved in immunostimulatory effects in in vitro human
peripherical mononuclear cells (PBMC). The extract could in-
duce IL-12 production by CD14-positive cell population con-
sisting of monocytes and macrophages. This response was
inhibited by anti-CD14 antibodies but interestingly alsoagainst anti-TLR4 showing the involvement of Toll-like recep-
tors in the immunostimulatory properties of the A. subrufes-
cens extract. Therefore, it is suggested that monocyte and
macrophage phagocytes are activated by A. subrufescens frac-
tions in a dose-dependent manner on CD14/TLR4 receptor
complex and NK activity (Kasai et al., 2004). It is speculated
that b-glucan or others components such mannan might be
recognized. Circulating dendritic cells do not produce IL-12
and IFN-c and not involved in the eliciting properties of A.
subrufescens in the in vitro test.
Daily administration of 32 mg or 64 mg of powdered
A. subrufescens signiﬁcantly promoted cytotoxicity activity of
liver mononuclear cells. The augmentation of NK cell cytotox-
icity was dependent on IFN-c but not T or NKT cells. NK
cells suppress tumor cells through a variety of effector mecha-
nisms, including the perforin/granzyme-containing granule-
mediated pathway, death-receptor pathway and IFN-c
mediated pathway (Smyth et al., 2002). Immunomodulatory
effects of A. subrufescens were also evaluated in Balb/cByj mice
(Chan et al., 2007). The extract of this mushroom exhibited a
signiﬁcantly increased serum IgG level, T-cell population and
phagocytic activity in mice. A. subrufescens fraction had been
shown to induce macrophages to secrete tumor necrosis
factor-alpha (TNF-a), interleukin (IL)-8 and nitric oxide
(NO) in vitro test (Sorimachi et al., 2001). After treatment with
Agaricus fractions, northern blot analysis showed that the in-
creases in cytokine and NO secretion were due to an increase
in cytokine mRNA or NO mRNAs. Moreover, the study of
signal substance secretion after A. subrufescens administration
exhibited the promotion of synthesis of the proinﬂammatory,
cytokine and chemokine in monocyte-derived dendritic cells
(MDDC) (Førland et al., 2010). TNF-a and IL-8 are pro-
inﬂammatory cytokines. It is well known as immunity against
fungal pathogen proceeds partly through pro-inﬂammatory
process via cytokines (Romani, 2008; Blanco and Garcia,
2008). Inﬂammatory processes are usually undesirable but
probably necessary to eliminate fungal pathogens. As men-
tioned above, the mode of immune defense against this type
of pathogens proceeds mainly through CMI. Recent advance
knowledge on fungal pathogens stated that lymphocytes-Th
17 response played an inﬂammatory role previously attributed
to uncontrolled Th1 responses (Romani 2008; 2011). Further-
more, nitric oxide was known as a stress mediator that in-
cluded the signal for vasorelaxation, neurotransmission and
cytotoxicity. Macrophage reactive nitrogen played an impor-
tant role in killing micro-organism and fungus (Nahrevanian,
2009). In contrast, it was recently observed in mice in vivo
model that nitric oxide (NO) negatively regulate the IL-12
mediated tumor regression and blocking the inducible nitric
oxide reductase by L-NAME dramatically increases tumor
suppression (Egilmez et al., 2011).
Concerning the A. subrufescens extracts, it has been shown
in in vitro and ex vivo studies that the extracts could promote
the synthesis of pro-inﬂammatory cytokines (IL-1b, IL-6, IL-8,
TNF-a), but not IL-12 or the anti-inﬂammatory cytokine IL-
10. Johnson et al. (2009) reported the study of Tryggestad
et al. (2007) that the transcription factor NF-jB was activated
by non-binding to TLR-4 but relative binding to TLR-2
(Tryggestad et al., 2007). TLR-2 was another type of pattern
recognition receptors (PRRs) which also facilitate production
of pro-inﬂammatory cytokines (Johnson et al., 2009; Romani
2011).
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Generally, dendritic cells activating lymphocyte T and lympho-
cyte T balance could also allow the elicitation of humoral
immunity via activation and recruitment of lymphocyte B cells.
The water-soluble proteoglycan and Andosan, a commercial
product from crude A. subrufescens, upregulated the in vitro
maturation of dendritic cells (Kim et al., 2005a, 2005b;
Forland et al., 2010). In vitro and ex vivo experiments on the to-
tal of heparinized blood of volunteers were shown that the
monocytes-derived dendritic cells from peripherical blood
mononuclear cells increased the cytokine and chemokines level.
After stimulating by A. subrufescens, the most abundant
cytokines are pro-inﬂammatory cytokine and chemocytokines
IL-8, G-CSF, TNF-a, IL-1b, IL-6, IL 17 andMIP-1b. The syn-
thesis of IL-2 and IFN c is also reported but not of IL-12 as pre-
viously mentioned. Therefore, only some Th1-type and Th17
type cytokines were up regulated whereas no anti-inﬂammatory
effect and the stimulation of Th2 cytokines in in vitro test.
Whereas ex vivo experiment, there is a release of different cyto-
kines including Th-1, Th-2, pro-inﬂammatory or anti-inﬂam-
matory as well as chemokines and leukocyte growth factor.
Therefore A. subrufescens extract mainly stimulates pro-inﬂam-
matory chemokine and cytokines in vitro or ex vivo.
Nevertheless, there have been some contradictory results in
immune responses of A. subrufescens extract. After 12 days of
consecutive administration of 20.4 g of Andosan, a commer-
cial mushroom extract which contains 82.4% of A. subrufes-
cens, the signiﬁcant reduction of pro-inﬂammatory cytokines,
mainly TNF-a, IL-1b, IL-2 and IL 17, are detected in healthy
volunteers. In addition, the other ﬁndings are slightly reduc-
tion of the pro-inﬂammatory IL-8, IFN-c or growth factor
G-CSF. The cytokine tests rather tend to be constant. The
inhibition of pro-inﬂammatory cytokines appears to be in a
dose dependant manner (Johnson et al., 2009). This is contra-
dictory with many studies as mentioned above. This is ex-
plained as the capacity of certain glucans to pass the murine
intestinal barriers. Ex vivo experiment with a healthy volunteer
suggests that heparinized blood has shown to be controversial
of immune stimulation of all pro-inﬂammatory cytokines
tested. The patients in the clinical trial test were suffered by
inﬂammatory bowel disease (IBD) (Førland et al., 2011). Vol-
unteers’ patients with Crohn’s disease (CD), widely regarded
as an autoimmune disease, and ulcerative colitis (UC) were ex-
posed to oral dose of A. subrufescens enriched mixture (Ando-
San). After 12 days repeated ingestion, the A. subrufescens
extract promotes anti-inﬂammatory effects without side ef-
fects. Most of the pro-inﬂammatory cytokines and chemokines
tested were downregulated and this was demonstrated ex vivo
with heparinized blood of exposed UC, CD and normal pa-
tients. Actually, most of the conclusion on downregulation
of the cytokines and chemokines results mainly of the observa-
tion made in presence of LPS.
There are contrary effects between in vivo and ex vivo assays
with normal patients, pro-inﬂammatory cytokines and chemo-
kines are controversial upregulated and downregulated,
respectively. This discrepancy was proposed by the antioxidant
potential of A. subrufescens (Ker et al., 2005; Oliveira et al.,
2007). The limited the absorption of large macromolecules
complex or bioactive molecule, such as b-glucans, across the
intestinal mucosa to the reticuloendothelial system and bloodof the gastrointestinal tracts. With CD and UC patients, the
same conclusive explanation is proposed, but the intestinal
barrier is hypothesized to be presumably selective permeable
to certain b-glucans bioactive fragments to body ﬂuids (blood
and lymphoid system) as in murine (Førland et al., 2011). This
was not veriﬁed whether the presence of molecules which dif-
fered from polysaccharides or PAMPS exerts immunosuppres-
sive effect on the innate immune system.
According to the above mentioned A. subrufescens extract,
it is rather conﬁrmed that the extract could exert both immu-
nostimulatory and immunosuppressive effects. b-Glucan deriv-
atives, proteoglucan, peptide-glucan appeared to be preferably
immunostimulating responses and indirectly promote anti-can-
cer effects. Whether immunosuppression is realized by the
same categories of molecules such as more or less branch poly-
saccharides or proteoglucans remains unclear. However, be-
cause of the immunosuppressive potential, safety assessment
of dietary edible commercial A. subrufescens should be
evaluated.
12. Antimicrobial activity
A. subrufescens has been extensively used in folk medicine
against life-threatening diseases worldwide. The protein-bound
polysaccharide, ‘‘proteoglucan’’, is a valuable compound that
enhances defense against invasive organisms (Hetland et al.,
1998). There are many reports of the effect of A. subrufescens
against bacterial infection (Bernardshaw et al., 2005, 2006). b-
Glucan is the main polysaccharide naturally found in aqueous
extracts of A. subrufescens. Hetland et al. (1998) proposed that
b-glucan could protect against the infection of bacillus Cal-
mette-Guerin (BCG) and Streptococcus pneumoniae (Klein)
(2000). Extracts from A. subrufescens are able to prevent S.
pneumoniae infection in mice (Bernardshaw et al., 2005) and
could reduce plaques formation of virus in cell culture
(Bruggemann et al., 2006). The extract exhibited anti-viral
activity in poliovirus type 1 (Faccin et al., 2007) and herpesvi-
rus (Bruggemann et al., 2006). Therefore, it is likely that A.
subrufescens extracts have therapeutic effects against bacterial
and viral infection. Thus intake of A. subrufescens extract may
be able to serve as an alternative to antibiotics.
13. Anti-allergy effect
There are a few studies in the anti-allergic test of A. subrufes-
cens extract (Ellertsen and Hetland, 2009). Most studies of this
mushroom involved the antitumor and anticancer tests in cell
or animal model, generally using mouse. Ellertsen and Hetland
(2009) used ovalbumin (OVA) as the model allergen. Anti-
OVA IgE levels, either treated with A. subrufescens extract be-
fore and after OVA immunization, were reduced in the serum
of mice. The extract may prevent the development of IgE-med-
iated allergy when given before and after allergen immuniza-
tion. Furthermore, there was a tendency to reduce Th2
relative to Th1 cytokine levels in the specimens. Previously,
pure b-glucans from yeast and fungi have been used to study
in allergic response with OVA. The results found increased
speciﬁc anti-OVA IgE levels in serum (Ormstad et al., 2000;
Instanes et al., 2004). Therefore, we speculated that b-glucans
or glucan protein or peptide complex from the mushroom ex-
tract might promote anti-allergic effect against allergen. A.
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hance Th1 response and had antiallergenic properties. This
process underwent via activation of macrophage by epithelial
cells that promote the differentiation of naı¨ve lymphocyte-T
cells into Th1 cells without apparently pro-inﬂammatory
consequences in mice (Bouike et al., 2011). Although, the re-
cent studies cannot fully answer in anti-allergic responses of
A. subrufescens extract. The mushroom extract may have
potential to use as a therapeutical substance against allergy
(Ellertsen and Hetland, 2009).
A. subrufescens extract has also shown to have an anti-
diabetic activity in diabetic rats (Kim et al., 2005a, 2005b;
Oh et al., 2010). Puriﬁed b-glucan from this mushroom was
shown to have anti-hyperglycemic, anti-hypertriglyceridemic,
anti-hypercholesterolemic and anti-arteriosclerotic activities
indicating overall anti-diabetic activity (Kim et al., 2005a,
2005b), which was also conﬁrmed in b-glucan removed semi-
puriﬁed fractions of A. subrufescens (Oh et al., 2010). An ethyl
acetate fraction of hot-water extract from this fungus was
tested on Streptozotocin-induced diabetic rats. Hypoglymeric
action indicated the fungus could be useful in the treatment
of diabetes mellitus (Oh et al., 2010).14. Production
Due to its nutritional and medicinal importance, A. subrufes-
cens is widely cultivated, although there is a huge demand for
this mushroom as health foods and in the pharmaceutical
industry (Souza Dias et al., 2004). Brazil is the largest commer-
cial producer of A. subrufescens (Souza Dias et al., 2004; De
Mendonca et al., 2005). Expansion of cultivation has therefore
occurred due to the high price on the international markets (De
Mendonca et al., 2005). However, the consumption of this fun-
gus in Brazil is low and has been restricted to small communi-
ties or higher cultural status groups (Souza Dias et al., 2004).
With its noticeable medicinal properties of A. subrufescens,
Brazilian mushroom growers are interested in growing and
exporting mushroom to many countries such as Australia,
Bolivia, Germany, Korea, India, Japan, South Africa,
Thailand, and the USA (De Mendonca et al., 2005). Several
Brazilian publicly funded institutions are engaged in research
on A. subrufescens concerning biochemical, physiological, ge-
netic aspects as well as the optimization and selection of com-
post, soil, casing techniques and growing conditions for this
fungus (Souza Dias et al., 2004). The production of this mush-
room is increasing worldwide due to their important medicinal
values and exotic slightly almond-like taste (Gyo¨rﬁ et al., 2010).
A. subrufescens normally requires temperatures of 25–28 C
for optimal mycelial growth and 22–25 C for fruiting (De
Mendonca et al., 2005). Temperature is a very important fac-
tor in A. subrufescens growth and fruiting because it is very
sensitive to extreme temperatures out of the optimal range
(De Mendonca et al., 2005). Higher temperatures decrease
yields due to the faster development of pathogens, while fruit-
ing body formation stops at low temperatures (De Mendonca
et al., 2005). Fruiting body formation is induced by providing
fresh air, lowering the temperature below 25 C, providing en-
ough humidity and performing heavy irrigation of the com-
post. The optimal humidity of the compost is approximately
60–70%. Whereas a humidity of 80–85% should be
maintained in the growing house. The subsequent harvestingperiods may require additional 30–60 days depending on envi-
ronment conditions (De Mendonca et al., 2005).
The productivity of A. subrufescens is related to the quality
of compost and choice of soil used as casing material (De
Siqueira et al., 2009). Agricultural wastes such as rice straw,
wheat straw, sawdust, rice bran, sugarcane bagasse and animal
manure have been used as substrates for mushroom cultivation
because they are cheap and readily available (Horm and Ohga,
2008). Various studies have attempted to optimize the compo-
sition of compost and casing material for mushroom cultiva-
tion. The casing layer is one of the most important phases of
A. bisporus and A. subrufescens cultivation (Colauto et al.,
2011). It covers the compost layer and is responsible for the
induction of fructiﬁcation. The function of the casing layer is
to protect the compost from drying, pest and disease (Colauto
et al., 2011). Depth of casing layer generally ranges from 3 to
5 cm, depending on the environmental variability of the grow-
ing house. The pH recommendation for casing soil for A.
subrufescens is 7.0 and 7.5 (Calvalcante et al., 2008). Zeid
et al. (2010) reported that the texture of different soils and
environment directly inﬂuenced precocity in A. subrufescens
yield and the production phase had a tendency of being longer
when soil + charcoal + calcitic lime were used as casing layer.
Colauto et al. (2010) proposed alternative materials instead of
peat to use in the casing layer. The increase in use of peat use
has resulted in a rapid depletion in nature and is a component
of the greenhouse effect due to the abundant liberation of CO2
through the aerobic decomposition of carbon. Furthermore,
some production areas in the world, especially in the southern
hemisphere, there are no large peat sources available (Colauto
et al., 2011). However, peat is predominantly used as a casing
layer worldwide. Increased macroporosity of the casing layer
provides better productivity. Lime schist is a promising alter-
native for mushroom production and it increases productivity
up to 92% compared with the control (Colauto et al., 2010).
The use of lime schist gave a good result in production ﬂush
and accumulated mass of fresh mushrooms when compared
to other casing layers (Colauto et al., 2011). The use of clay
soil as a casing layer decreases productivity, due to rapid com-
paction and low water retention capacity. Cattle and sugar-
cane compost supplemented with sawdust and rice bran also
promoted the development of A. subrufescens (Horm and
Ohga, 2008). The high amount of organic matter in the casing
soil might increase undesirable microorganisms. Soybean ﬁber
is also an appropriate substrate for A. subrufescens develop-
ment. It is more porous, has high water absorption capacity
and high nutrients for mycelial growth. Soybean ﬁber has high
N content, which is an essential nutrient to promote the
growth of mycelium (Junior et al., 2010). Some minerals in
compost stimulate the mushroom fructiﬁcation such as zinc,
copper and manganese. They have an important role in the
elimination of quinine, which is a substance that inhibits fruc-
tiﬁcation (Calvalcante et al., 2008). Thus we concluded that
various factors should be considered for A. subrufescens culti-
vation such as temperature, humidity of substrate and growing
house, and composition of compost and casing layer. Nutri-
ents and minerals are essential for promoting the mycelial
growth and fructiﬁcation.
More widespread international cultivation of A. subrufes-
cens would reduce the price of this mushroom, although it
would reach more consumers. The price would be cheaper in
Brazil where it is presently mostly produced and therefore could
Figure 2 Products from Agaricus subrufescens. (A) fresh mushroom (Http://www.diabetichealthyresources.com/can-a-mushroom-from-
brazil-be-the-secret-to-brain-health/, 2010), (B) dried mushroom (Http://www.sunwahfoods.com/subpages/home.php, 2010), (C) nutrient
supplement (Http://www.sunfood.com/buy/1/10/Agaricus-blazei-Mushroom-Science-90-veg-ca, 2010), (D) coffee (Http://quezon-
city.olx.com.ph/brazilian-coffee-8-in-1-slimming-coffee-iid-6, 2010) and (E) shampoo (Http://www.vitamegacosmetic.com/, 2010).
Agaricus subrufescens: A review 141be used by Brazilian consumers (De Mendonca et al., 2005).
Presently Brazil exports A. subrufescens, including as fresh,
dried, sliced or powdered mushrooms. The development of A.
subrufescens products would increase the product value in the
market (DeMendonca et al., 2005). It is used as nutrient supple-
ment because of the high content of b-glucan (Ohno et al.,
2001). Consumers can ﬁnd the product of this mushroom in var-
iable forms. Beside fresh fruiting bodies, this mushroom is sold
in a pulverized form, which is supplied in capsules or pills or as
an extract produced using hot water (Gyo¨rﬁ et al., 2010). Fur-
thermore, many medicinal mushrooms, including A. subrufes-
cens, have been used as additive ingredients in cosmetic
products. Hyde et al. (2010) reported on some cosmetic prod-
ucts containing mushrooms. Vitamega is a Brazilian cosmetic
company that used A. subrufescens as the main bioactive ingre-
dient of their products. Some products from A. subrufescens
mushrooms on international markets are illustrated in Fig. 2.
15. Toxicological problems
Although eating cultivated mushrooms or their extracts is
thought to provide medicinal and other beneﬁts, there are
few studies on the safety of this practice. A. subrufescens has
long been consumed as a culinary and supplementary food
and has not been reported to be directly toxic or carcinogenic
to humans. Nevertheless, we need to be cautious and consider
if there are any deleterious effects from eating A. subrufescens.
The content of poisonous microelements in fruiting bodies of
this fungus has been reported by Gyo¨rﬁ et al. (2010). The
content of Cobalt (Co), Molybdenum (Mo), Selenium (Se),
Vanadium (V) are under detectable limits which are about
0.1–0.2 mg/kg of dry matter. However, the detectable amount
of cadmium (Cd), is about 2–17 mg/kg of dry matter (Gyo¨rﬁ
et al., 2010) and must be considered. According to the result,
the amount of Cd found is likely reﬂected in the actual Cd
accumulation in A. subrufescens.The major concern over the use of A. subrufescens is the
problem of the hydrazine content. A. subrufescens has been
studied and assessed for possible side-effects of agaritine and
its derivatives (Stijve et al., 2003; Nagaoka et al., 2006) as these
are suspected to be genotoxic and possible carcinogenic or
tumorigenic agents. This molecule is thought to be capable
of binding to the DNA of organs after administration to mice
models (Shephard and Schlatter, 1998). The genotoxicity of
agaritine is however, very limited. The cumulative lifespan of
cancer risk obtained from agaritine consumption is probably
estimated at 10(5). The possible deleterious effect of the accu-
mulative hydrazine was ﬁrst reported from populations living
in industrial settings with rocket fuel contamination. Toth
(1996) believed that most hydrazines and derivatives (more
than 80%), including fungal hydrazine, are probably harmful
due to being carcinogens. Agaritine is a substrate for gam-
ma-glutamyl transpeptidase and is converted into a highly
reactive diazonium ion derivative that could bind to protein
which promotes apparent mutagenicity and gives a positive
response in the Ames test (Walton et al., 1997a,b). However,
the results from Walton et al. (1997a,b) contradict those of
Paparaskeva-Petrides et al. (1993) and Endo et al. (2010),
who showed that agaritine did not activate the umu gene of
Salmonella, which reacted to carcinogens (Endo et al., 2010).
4-methylphenylhydrazine hydrochloride, a derivative of agari-
tine was reported to induce 24% ﬁbrosarcomas in Swiss mice
administrated with this compound (Toth et al., 1977; Toth
and Nagel, 1981).
In 2006, the Ministry of Health, Labour and Welfare of
Japanassessed the safety of products containingA. subrufescens.
The results showed that agaritine and derivatives were found
in dried A. subrufescens fruiting bodies and canned mush-
room products containing A. subrufescens (Nagaoka et al.,
2006). Firenzuoli et al. (2008) also speculated that fungal
hydrazine (hydroxyphenyl hydrazine) probably stimulated
proteolysis giving rise to hydrazine-mediated DNA strand
142 K. Wisitrassameewong et al.scissions and metabolized toxic intermediates capable of dam-
aging cellular macromolecules. The incubated hydrazine in
hemolysate caused strand scission of DNA as well as an in-
crease in the proportion to protein concentration of the
hemolysate (Runge-Morris et al., 1994) Runge-Morris et al.
(1994) also suggested that oxygen-relative organic free radi-
cals played a dominant role in hydrazine-mediated DNA
strand scission. Hydrazine and its derivatives had been found
in A. subrufescens and its products using HPLC with Fluores-
cence Derivatization (Nagaoka et al., 2006).
Mukai et al. (2006) had reported on side effects of
A. subrufescens and stated that the mushroom might induce se-
vere hepatic dysfunction in cancer patients. Three patients with
severe hepatic dysfunction were taking the mushroom extract.
After treatment with the mushroom extract, one of the three
patients developed deterioration of the liver function. It was,
however, difﬁcult to afﬁrm the cause of deterioration of liver
function in these patients. It should be noted that concurrent
use of the mushroom extract made differential diagnosis com-
plicated. The long-term intake of feed supplement with A.
subrufescens did not result in visible alterations in the kidney
function indices (Stutz et al., 2009). Lee et al. (2008) had
shown no carcinogenicity or other adverse health effects in
rats after intake of A. subrufescens extracts over 2 years.
A. subrufescens fruiting body extract was also studied to test
its potential in modifying tumor development in a medium-
term multi-organ carcinogenesis bioassay (Doi et al., 2010).
No modifying potential on tumor development resulted.
There are only limited reports on toxicological and epide-
miological effects of intake of fungal hydrazine as well as
mechanisms of action where reports are contradictory.
Although hydrazine compounds are regarded as toxic, many
patients use these compounds for disease treatment. For exam-
ple, procarbazine is an anti-neoplastic chemotherapy drug
used for the treatment of Hodgkin’s lymphoma and brain
cancers. Procarbazine is well-known as causing gonadotoxic,
teratogenic and hepatic disorders. This is however, character-
istic of many cancer drugs. More recently, there have been
some contradictory reports concerning the effects of agaritine
from A. subrufescens. Agaritine puriﬁed from this mushroom
has a direct anti-tumor activity against leukemic tumor cells
in vitro (Endo et al., 2010) and moderately induced apoptosis
through caspase activation in the leukemic cell line U937
(Akiyama et al., 2011). The beneﬁcial or toxicological effect
of a bioactive substance often depends on its concentration;
it will occasionally have beneﬁcial properties at low concentra-
tions but could be toxic at high concentrations. However, to
ensure the safety of long-term using of A. subrufescens, further
research may be required to ﬁnd the optimal method to re-
move or reduce the content of agaritine in A. subrufescens ex-
tracts (Sorimachi and Nakamoto, 2011). Further toxicology
studies still need to completely conﬁrm the safety of the use
of A. subrufescens.16. Conclusion
A subrufescens has been widely used as a food over many dec-
ades. Because it has potential medicinal properties, the mush-
room has become a hot topic in many research areas. Scientiﬁc
studies have conﬁrmed various medicinal beneﬁts of the mush-
room, such as anti-cancer, anti-microbial and biomodulatoryeffects. Several bioactive compounds that can be developed
and used as therapeutic agents have been identiﬁed and char-
acterized from this species. Clinical trial data are however, still
necessary to determine whether A. subrufescens provides real
medicinal beneﬁts (Firenzuoli et al., 2008). Toxicological prob-
lems may also be an issue. Toxicology data should be assessed
especially with known bioactive compounds such as agaritine,
blazein and A. subrufescens fruiting bodies, but overall epide-
miological data are needed linking intake with any possible
side effects. Safety issues in particular should focus on the tox-
icity and carcinogenicity of agaritine and its derivatives in this
mushroom. It would be beneﬁcial to the success of A. subrufes-
cens if it was shown not to give rise to any toxicological effects.
A. subrufescens should be an excellent future alternative
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